349 filings
Page 4 of 18
8-K
1v1hga5m
11 Feb 20
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
6:08am
8-K
76paj56
3 Jan 20
Entry into a Material Definitive Agreement
4:33pm
8-K
h7qs odxwe0wo
7 Nov 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
18lok96b50nwcxm0a
21 Oct 19
Entry into a Material Definitive Agreement
8:57am
8-K
hwqpowwi
27 Aug 19
Entry into a Material Definitive Agreement
4:31pm
8-K
gzgm vw3v3ja
14 Aug 19
Departure of Directors or Certain Officers
4:37pm
8-K
pk1ibz
17 Jul 19
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
9:07am
8-K
485tl
27 Jun 19
Validated, Pre-Clinical Success Shown in Modifying the Regulation of the SNCA Gene Which Encodes Alpha-Synuclein Expression
7:24am
8-K
dq4z4p gep83xvavi2
17 Jun 19
Entry into a Material Definitive Agreement
9:55pm
8-K
9m51ixa7an
21 May 19
Seelos Therapeutics Reports Q1 2019 Pipeline Update
2:40pm
8-K
2ohyoesl5fm0nh71x s7
13 May 19
Departure of Directors or Certain Officers
5:02pm
8-K
wiurm rgjo
8 Apr 19
Changes in Registrant's Certifying Accountant
4:15pm
8-K
ciczg
26 Mar 19
Departure of Directors or Certain Officers
4:55pm
8-K
f8j30
8 Mar 19
Entry into a Material Definitive Agreement
6:39am
8-K/A
8kpwr
1 Mar 19
Departure of Directors or Certain Officers
4:19pm
8-K
ainpg8k hbxso7097
19 Feb 19
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma
8:00am
8-K
jsxqxfy2r
6 Feb 19
Entry into a Material Definitive Agreement
4:15pm
8-K/A
9p07gns42lr 0qdjw4x4
30 Jan 19
Financial Statements and Exhibits
4:15pm
8-K
3yqjnhfa
24 Jan 19
Other Events
8:06am
8-K
kdoq40wpco792md945i3
24 Jan 19
Completion of Acquisition or Disposition of Assets
8:05am